NovAliX enters into fragment-based drug discovery alliance with Kyowa Hakko Kirin
17-Jan-2013
- France
NovAliX SAS announced that it has entered into a fragment-based drug discovery alliance with Kyowa Hakko Kirin Co., Ltd., Japan.
Within the alliance, the companies will collaborate to develop novel drug candidates against protein-protein interaction targets.
Under the terms of the agreement NovAliX will receive technology access fees as well as further research funding payments and milestones.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.